Courtesy of Benzinga.
Analysts at Jefferies initiated coverage on shares of ProQR Therapeutics (NASDAQ: PRQR) with a Outperform rating.
The target price for ProQR Therapeutics is set to $24.
ProQR Therapeutics’ shares fell 3.86% to close at $15.46 on Friday.
Latest Ratings for PRQR
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2014 | Jefferies | Initiates Coverage on | Outperform |
View More Analyst Ratings for PRQR
View the Latest Analyst Ratings
Posted-In: JefferiesInitiation Analyst Ratings